Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study, the Kitanagoya Genome (KING) Study for the Local Residents of Kitanagoya, Japan

Cardiovascular disease is a complex multifactorial and polygenic disorder that is thought to result from an interaction between a person's genetic make up and various environmental factors. Although many studies have revealed that several genetic variants increase the risk of cardiovascular disease, the results of these studies remain controversial. The purpose of this study is to identify polymorphisms that confer susceptibility to cardiovascular disease and to clarify the adequacy of reported susceptibility gene polymorphisms. To complete this purpose, we will prospectively study over 5,000 local residents in whom relationship between these polymorphisms and occurrence of cardiovascular disease over 5 years.

Study Overview

• Status: Unknown
• Conditions: Myocardial Infarction; Coronary Disease; Healthy; Cerebral Infarction

• Study Type: Observational
• Enrollment (Anticipated): 7000

Contacts and Locations

• Study Contact: Name: Mitsuhiro Yokota, MD, PhD; Phone Number: 369 +81-52-759-2111; Email: myokota@dpc.aichi-gakuin.ac.jp
• Study Contact Backup: Name: Mitsuhiro Yokota, MD, PhD; Phone Number: +81-52-744-5515; Email: mitsuhiro.yokota@theranos-inst.com

Study Locations

• Japan
  • Aichi
    • Nagoya, Aichi, Japan, 464-8651
      • Recruiting
      • Department of Genome Science, School of Dentistry, Aichi-Gakuin University
      • Contact: Mitsuhiro Yokota, MD, PhD; Phone Number: 369 +81-52-759-2111; Email: myokota@dpc.aichi-gakuin.ac.jp
      • Principal Investigator: Mitsuhiro Yokota, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy subjects who undergo community-based annual health check in Kitanagoya city

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Collaborators and Investigators

• Sponsor: Nagoya University
• Collaborators: Aichi Gakuin University
• Investigators: Study Chair: Mitsuhiro Yokota, MD, PhD, Department of Genome Science, School o Dentistry, Aichi-Gakuin University

Publications and helpful links

General Publications

• Nakatochi M, Ichihara S, Yamamoto K, Naruse K, Yokota S, Asano H, Matsubara T, Yokota M. Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease. Clin Epigenetics. 2017 May 15;9:54. doi: 10.1186/s13148-017-0353-3. eCollection 2017.
• Nakatochi M, Miyata S, Tanimura D, Izawa H, Asano H, Murase Y, Kato R, Ichihara S, Naruse K, Matsubara T, Honda H, Yokota M. The ratio of adiponectin to homeostasis model assessment of insulin resistance is a powerful index of each component of metabolic syndrome in an aged Japanese population: results from the KING Study. Diabetes Res Clin Pract. 2011 Jun;92(3):e61-5. doi: 10.1016/j.diabres.2011.02.029. Epub 2011 Mar 31.
• Tanimura D, Shibata R, Izawa H, Hirashiki A, Asano H, Murase Y, Miyata S, Nakatochi M, Ouchi N, Ichihara S, Yasui K, Yoshida T, Naruse K, Matsubara T, Yokota M. Relation of a common variant of the adiponectin gene to serum adiponectin concentration and metabolic traits in an aged Japanese population. Eur J Hum Genet. 2011 Mar;19(3):262-9. doi: 10.1038/ejhg.2010.201. Epub 2010 Dec 8.
• Asano H, Izawa H, Nagata K, Nakatochi M, Kobayashi M, Hirashiki A, Shintani S, Nishizawa T, Tanimura D, Naruse K, Matsubara T, Murohara T, Yokota M. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia. 2010 Feb;53(2):234-46. doi: 10.1007/s00125-009-1517-2. Epub 2009 Sep 1.

Study record dates

Study Major Dates

• Study Start: May 1, 2005
• Primary Completion: December 7, 2022
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: December 6, 2005
• First Submitted That Met QC Criteria: December 6, 2005
• First Posted (Estimate): December 7, 2005

Study Record Updates

• Last Update Posted (Estimate): September 21, 2007
• Last Update Submitted That Met QC Criteria: September 20, 2007
• Last Verified: September 1, 2007

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Ischemia; Pathologic Processes; Necrosis; Myocardial Ischemia; Heart Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Brain Ischemia; Stroke; Brain Infarction; Myocardial Infarction; Infarction; Coronary Disease; Cardiovascular Diseases; Cerebral Infarction
• Other Study ID Numbers: NU-05-G-0001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No